Results 91 to 100 of about 182,433 (270)
PLoS ONE, 2016 BackgroundHepatitis C virus infection is a global health problem. New direct-acting antiviral agents have been recently approved. However, due to their high cost and some genotypes remaining difficult to treat, interferon-based therapy with pegylated ...
Ran Chen +4 more
doaj +1 more source
Journal of Medical Case Reports, 2012 Introduction The combination of polyethylene glycol (PEG)ylated interferon (pegylated interferon) and ribavirin has been shown to be an effective treatment for chronic hepatitis C virus. In general, common side effects related to this combination therapy
Lahbabi Mounia +4 more
doaj +1 more source
Journal of Medical Case Reports, 2010 Introduction Hepatitis-associated aplastic anemia is a common syndrome in patients with bone marrow failure. However, hepatitis-associated aplastic anemia is an immune-mediated disease that does not appear to be caused by any of the known hepatitis ...
Ioannou Savvas +3 more
doaj +1 more source
Journal of Pediatric Gastroenterology and Nutrition, EarlyView.Abstract Objectives In adults with chronic hepatitis C (CHC) and advanced fibrosis, hepatocellular carcinoma (HCC) surveillance is recommended after achieving a sustained virologic response (SVR). However, post‐SVR surveillance strategies for children remain unclear. The aim of this study was to assess the durability of SVR and determine an appropriate
Hitoshi Tajiri +6 more
wiley +1 more source
, 2018 Pooled risk ratio of sustained virological response at weeks 12 and 24 after the end of treatment between simeprevir plus pegylated interferon-ribavirin and pegylated interferon-ribavirin.
Thunyarat Anothaisintawee (840641) +4 more
core +1 more source
Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C. [PDF]
, 2003 Pegylated interferons have recently been approved for treatment of hepatitis C. The safety of these formulations is reported to be similar to that of non-pegylated interferon.
Thomas, William L Jr +2 more
core +1 more source
Arquivos de Gastroenterologia, 2004 AIM: Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C.
Elson V. Martins Jr., Ana K. Gaburri
doaj +1 more source
Pegylated interferon α2b versus pegylated interferon α2a for chronic hepatitis C: The unreached goal of superiority [PDF]
Journal of Hepatology, 2009 Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, for the IDEAL Study Team. Background
openaire +3 more sources
JEADV Clinical Practice, EarlyView.ABSTRACT Mycosis fungoides is a misnomer that means ‘mushroom‐like fungal disease’, but it is, in fact, the most common form of cutaneous T‐cell lymphoma. The diagnosis of mycosis fungoides is often delayed due to non‐specific symptoms and cutaneous signs that mimic other common benign inflammatory dermatoses.
Ji Fung Yong +5 more
wiley +1 more source
Acute pancreatitis associated with boceprevir: a case report
Brazilian Journal of Infectious Diseases, 2014 Approximately 170 million people are infected with hepatitis C, and the sustained virological response rate to treatment with pegylated interferon and ribavirin is 30–50%. In an attempt to improve the chances of cure, boceprevir is being added to therapy,
Juliana Miguel Bilar +4 more
doaj +1 more source